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The aggregation of α-synuclein is a central event in Parkinsons’s disease and related synu-
cleinopathies. Since pharmacologically targeting this process, however, has not yet resulted in
approved disease-modifying treatments, there is an unmet need of developing novel methods
of drug discovery. In this context, the use of chemical kinetics has recently enabled accurate
quantifications of the microscopic steps leading to the proliferation of protein misfolded
oligomers. As these species are highly neurotoxic, effective therapeutic strategies may be
aimed at reducing their numbers. Here, we exploit this quantitative approach to develop a
screening strategy that uses the reactive flux toward α-synuclein oligomers as a selection
parameter. Using this approach, we evaluate the efficacy of a library of flavone derivatives,
identifying apigenin as a compound that simultaneously delays and reduces the formation of
α-synuclein oligomers. These results demonstrate a compound selection strategy based on
the inhibition of the formation of α-synuclein oligomers, which may be key in identifying small
molecules in drug discovery pipelines for diseases associated with α-synuclein aggregation.
https://doi.org/10.1038/s42004-020-00412-y OPEN
1 Centre for Misfolding Diseases, Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK. 2 Paulson School of Engineering and Applied
Sciences, Harvard University, Cambridge, MA 02138, USA. 3 Department of Chemistry, Division for Biochemistry and Structural Biology, Lund University, 221
00 Lund, Sweden. ✉email: mv245@cam.ac.uk









α-Synuclein is an intrinsically disordered protein involvedin the maintenance of presynaptic vesicle pools, theirfusion to plasma membranes and their release from
synaptic termini1–5. Mutations and duplications of the α-
synuclein gene have been implicated in the early onset of
Parkinson’s disease6,7, a neurodegenerative disorder that affects
the motor system8,9. This disease is currently incurable,
with available drugs capable of improving its symptoms
but unable to arrest its onset and progression10–19. At the
molecular level, this disease, as well as a range of related con-
ditions collectively known as synucleinopathies, is characterised
by the presence of deposits predominantly comprised by α-
synuclein20. Consequently, the inhibition of α-synuclein
aggregation has emerged as a strategy for therapeutic inter-
vention for these disorders12,13,16,21–26. Despite the focus of
research efforts on this target, however, the mechanism of α-
synuclein aggregation remains to be fully elucidated. Moreover,
there is still a need to develop quantitative experimental
methods to enable accurate assessments of the effects of can-
didate anti-aggregation compounds.
It is also becoming increasingly clear that small, transient oli-
gomeric assemblies, rather than mature, highly ordered fibrils, are
highly damaging species associated with α-synuclein aggregation,
as they are able to cause, in particular, lipid membrane disruption
and cellular toxicity27–32. Therefore, it may not be sufficient to
inhibit the formation of fibrils, as their measurement does not
readily account for the accumulation of damaging oligomeric
species33. Therefore, compounds that inhibit fibril formation may
leave unchanged the prevalence of oligomers or even favour their
formation. For this reason, interventions aimed at reducing the
reactive flux towards oligomers must take into account the
complex interplay between the different microscopic steps of
aggregation, as it has been recently shown in the case of the
amyloid β peptide34.
In the case of α-synuclein, developing drug discovery strategies
based on our understanding of its aggregation process is parti-
cularly important given that the specific microscopic steps in the
aggregation of this protein are highly sensitive to the cellular
environment and solution conditions. In particular, the rate of
fibril-catalysed secondary nucleation, which is responsible for the
rapid proliferation of aggregates, and thus thought to be a major
source of toxic α-synuclein oligomers, can change by over four
orders of magnitude depending on the pH35. As the reactive flux
towards oligomeric species depends on a non-linear combination
of the various microscopic rates of the constituent aggregation
processes, it is challenging to identify compounds that reduce this
flux across the range of conditions present in biological systems
without employing a method for its accurate quantification as a
metric to describe drug efficacy.
In this work, we illustrate a screening strategy to achieve this
result. Our approach is based on recent advances in the under-
standing of the conditions that influence α-synuclein aggregation,
such as pH and the effects of varying ratios of seed fibrils to free
monomers. This increased understanding has given rise to a set of
different experimental assays through which α-synuclein aggre-
gation may be measured by thioflavin T (ThT) fluorescence,
which individually recapitulate fibril elongation and secondary
nucleation, whereby new aggregates nucleate on existing fibril
surfaces. Combined together, these assays enable a detailed
characterisation of α-synuclein aggregation process in vitro35,36.
Crucially, this approach involves a chemical kinetics analysis that
enables the quantification of the populations of the intermediate
species (i.e. the oligomers) from the measurement of the products
(i.e. the fibrils)37,38. These experiments occur under quiescent
conditions and have been shown to be reproducible under con-
sistent solution conditions35,36.
The use of this kinetic strategy has previously enabled the
detailed study of α-synuclein aggregation in terms of its micro-
scopic processes under quiescent conditions, providing crucial
insights of more direct physiological relevance than those
resulting from assays based on shaking of α-synuclein solutions35.
More specifically, in our approach, the initiation of the aggrega-
tion process is studied by means of two seed-induced aggregation
assays that recapitulate fibril elongation and fibril amplification.
Fibril elongation, which involves the addition of protein mono-
mers to fibril ends, is studied in the presence of high con-
centrations of preformed fibrils at neutral pH35,39 and the
autocatalytic amplification of fibrils via secondary nucleation is
studied in the presence of low concentrations of preformed fibrils
under mildly acidic conditions35,39,40.
Our kinetics-based screening approach enables the testing of
potential inhibitors for their ability to interfere with the micro-
scopic processes of α-synuclein aggregation and thus with the
formation of oligomeric species. We show that this approach can
be used to establish a structure–kinetic activity effect34 in order to
quantify the reduction of α-synuclein oligomers induced by sys-
tematic changes to candidate small molecule inhibitors.
Results
A kinetics-based drug discovery strategy to target oligomers in
synucleinopathies. In this work, we set out to develop a strategy
for the identification of small molecules able to interfere with the
aggregation process of α-synuclein in a specific manner, whereby
the flux towards oligomeric species is reduced.
Our study consists of a structure–kinetic activity effect analysis
of a selected small molecule scaffold, wherein we characterise in
detail a series of derivatives against key microscopic steps of α-
synuclein aggregation. We thus identify the manner in which
different derivatives of this scaffold affect the different micro-
scopic aggregation steps. Specifically, we describe the aggregation
process using a master equation approach41,42, which quantifies
the populations of each aggregating species in terms of the
elementary events of aggregation, including fibril elongation
(Eq. 1) and secondary nucleation (Eqs. 2–7) (Fig. 1). We
concentrate our attention on secondary nucleation in particular,
as it has recently been shown that the autocatalytic nature of this
process is more effective than primary nucleation in producing
oligomeric species42. In this master equation framework, we use
k+ and k2 to denote the rate constants of elongation and
secondary nucleation, respectively, while n2 denotes the reaction
order of secondary nucleation.
Fig. 1 Schematic view of the dominant microscopic processes responsible
for the proliferation of α-synuclein oligomers. The inhibition of oligomer
proliferation should balance the autocatalytic generation of oligomers by
secondary nucleation and the depletion of oligomers by fibril elongation. r+
is the apparent rate of fibril elongation and r2 is the apparent rate of
secondary nucleation.
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This master equation approach can be generalised to account
for the presence of inhibitors, as it can be shown that the topology
of the aggregation network remains unchanged in their presence,
i.e. the form of the solution to the aggregation kinetics remains
unchanged33. This aspect of the approach allows us to interpret
inhibited aggregation kinetics in terms of effective rate para-
meters that are functions of the inhibitor concentration.
We initially identified a molecule with the flavone scaffold
(FLV; Fig. 2), which affects the aggregation of α-synuclein
according to previous reports43–45. This molecule is a convenient
tool compound for research, and may perhaps be of therapeutic
interest, as it has been reported to be neuroprotective in animal
models of age-related pathology46. We thus employed this
molecule to investigate derivatives with varying numbers and
positions of hydroxyl moieties. This strategy resulted in the
selection of six derivatives for screening (Fig. 2). We note that
these compounds may mediate the inhibition of α-synuclein
aggregation in a number of ways, both as inhibitors and as
promoters, including undergoing an interaction with α-synuclein
side chains by forming quinoprotein adducts47–50.
Quantification of reactive flux towards oligomers in α-synuclein
aggregation. Oligomeric species produced on the aggregation
pathways of disease-associated proteins are often able to induce
cytotoxicity to a more severe degree than mature, fibrillar
aggregates27–32. Indeed, α-synuclein has been shown to form
oligomeric aggregates that interconvert between structural sub-
types and have varying levels of cytotoxicity mediated by their
structures31,32. In particular, α-synuclein oligomers possessing a
higher degree of cross-β sheet structure, and increased proteinase
K resistance, are more harmful in various assays than their less
ordered counterparts31,32.
Addressing the issue of intermediate species formation from a
therapeutic perspective has proven challenging, not least because
these species are transient, disordered and difficult to characterise
in situ31,32,37. However, when abrogating oligomer formation can
be considered as a therapeutic target, the need exists to elucidate
the rate and quantity of oligomeric species formation as a
function of typical fibril-formation kinetic readouts so that, in
turn, drug candidates can be screened for their ability to inhibit
this process. In particular, the generation of aggregates via
secondary nucleation is largely dependent on both the secondary
nucleation rate (r2) as well as the fibril elongation rate (r+)34.
These microscopic steps differentially affect the generation of
toxic oligomers over time, and thus the prediction of such toxic
oligomeric species in the presence of the small molecules requires
a simultaneous analysis of both r+ and r2 as gathered from the
kinetic data33,34. While biophysical characterisation of these
intermediate species remains challenging, we leverage kinetic
parameters in this work to access a predictive model of the flux
towards on-pathway oligomeric species.
Secondary nucleation in α-synuclein aggregation. We explored
first the ability of the derivatives to inhibit secondary nucleation.
To this end, we incubated monomeric α-synuclein with 0.0025
molar equivalents of preformed fibrils in the absence and pre-
sence of 0.5 molar equivalents of the derivatives, relative to α-
synuclein monomers, under mildly acidic conditions35,36,39, and
analysed the rate of fibril amplification by determining the change
of mass fraction of fibrils at the half-time of the aggregation by
fitting a generalised logistic function (Eq. 2). Under these con-
ditions, we found that the flavone derivatives exerted differential
effects on the aggregation of α-synuclein. In particular, while
baicalein and morin were able to accelerate slightly the secondary
nucleation process of α-synuclein, other flavone derivatives were
shown to inhibit this process instead (Fig. 3). As small molecules
may perturb the monitoring of the aggregation process51, end-
point fibrils from this reaction were observed by transmission
electron microscopy (Fig. S1).
Elongation of α-synuclein aggregates. We next investigated the
ability of the various flavone derivatives to inhibit α-synuclein
fibril elongation. For this purpose, we determine the effective rate
of α-synuclein fibril elongation, r+, under the same conditions
used in the secondary nucleation assay (pH 4.8, 37 °C; Fig. 4), in
order to garner comparable effective rates for both the elongation
and secondary nucleation processes. These conditions were cho-
sen after scanning a range of values to find those suitable for both
assays simultaneously. We found that the flavone derivatives only
affected mildly the aggregation of α-synuclein (Fig. 4). Thus the
inhibitory or accelerating effects as observed in a low-seeded
condition is likely to be due to the changes in the secondary
nucleation step, rather than the elongation process.
Using microscopic rates to estimate oligomer formation. Using
the master equation framework, we derived a mathematical
expression for the flux towards oligomers (Eqs. 8–12). Incor-
porating the effective rates of aggregation into this expression
allows us to estimate the effect of different compounds on the flux
towards oligomers. Our analysis shows that different compounds
have different abilities to affect the flux towards oligomers in the




























Flavone 7-Hydroxyflavone Apigenin Baicalein
ScutellareinMorin5,6,7-Trimethoxyflavone
Fig. 2 List of the six flavone derivatives tested in this work against the microscopic processes of α-synuclein aggregation. From the flavone scaffold
(FLV), we selected 5,6,7-trimethoxyflavone (TMF), 7-hydroxyflavone (7HF), apigenin (API), baicalein (BAI), scutellarein (SCT) and morin (MOR), with
varying numbers and positions of hydroxyl moieties.
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observed similar effects on secondary nucleation in the case of
apigenin and 7-hydroxyflavone (Fig. 2), but apigenin performed
better in decreasing the total area under the oligomer flux curve
(that is, the total number of oligomers formed) and decreasing the
peak height, as well as in delaying the peak time of the oligomer
flux curve (Fig. 6a–e).
Our analysis shows that the flux towards oligomers is not
controlled by a single microscopic step of aggregation but rather
by a complex combination of different aggregation rates. This
conclusion follows if one considers the apparent rate of secondary
nucleation (r2) as a source of new oligomeric intermediates and
the apparent rate of elongation of oligomers into fibrillar material
(r+) as a sink that consumes the population of these new
aggregates as they grow to mature fibrils (Fig. 6f). Thus the
prevalence of oligomeric species in the overall aggregation
reaction at any one time is dependent on an interplay between
the rates of formation and depletion of oligomers. This interplay
dictates a number of characteristic features of the flux towards
oligomers over time (area under the curve, peak height and peak
time, Fig. 6a–d) and may be visualised, as phase diagrams, in
terms of r+ and r2 (Eqs. 13–19 and Fig. 6g). The area under the












This approach allows us to consider the properties of the resulting
oligomer flux curve as parameters through which we can optimise
compounds for drug design. Notably, this design cannot be directed
towards an optimum for both parameters concurrently. In
particular, the optimum design strategies for a compound affecting
the peak area or the peak time would involve the optimisation of the
effects on both r+ and r2, while designing for peak height may
involve optimising only inhibition of the secondary nucleation
process. These equations may also be generalised to include
parameters for fibril fragmentation and dissociation, as well as





























Fig. 3 The flavone derivatives affect the α-synuclein secondary nucleation step differentially. a Normalised change in ThT fluorescence when 20 µM
monomeric α-synuclein was incubated with 50 nM preformed seed fibrils at pH 4.8 and 37 °C in the absence (DMSO control (black)) and presence of
10 µM (0.5 molar equivalents, relative to monomeric protein) of flavone derivatives (flavone (red), 5,6,7-trimethoxyflavone (magenta), 7-hydroxyflavone
(purple), apigenin (blue), baicalein (light green, which speeds up the process), scutellarein (brown), morin (dark green)). Yellow overlay indicates
corresponding generalised logistic fit (Eq. 2). b Rate of α-synuclein fibril amplification, normalised relative to the DMSO control. Error bars represent the
standard error of the mean of three experimental replicates each containing three technical replicates. Statistical analyses represent two-way ANOVA
results where **P≤ 0.0021.













































Fig. 4 Derivation of the elongation rate constant, r+, under secondary nucleation conditions. a Normalised change in ThT fluorescence when 20 µM
monomeric α-synuclein was incubated in the absence (DMSO control (black)) and presence of 0.5 molar equivalents of flavone derivatives (flavone (red),
5,6,7-trimethoxyflavone (magenta), 7-hydroxyflavone (purple), apigenin (blue), baicalein (light green), scutellarein (brown), morin (dark green)) with 30%
preformed seed fibrils, relative to monomeric protein, at pH 4.8 and 37 °C under quiescent conditions. Dotted lines indicated the linear fit to the initial time
points to obtain r+. b Value of the elongation rate constant, r+, for each compound, relative to DMSO control. Error bars represent the standard deviation
over three technical replicates.
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observed to be negligible for α-synuclein under quiescent
conditions40.
Conclusions
We have described an approach that enables the characterisation
of the effects of small molecules on the oligomer production via
secondary nucleation in α-synuclein aggregation. We have then
shown that it is possible to identify a compound (apigenin) that
reduces the number of oligomers formed during the aggregation
process. The results of a structure–kinetic activity effect study
show that the specific positioning of hydroxyl groups on the FLV
is important for conferring an enhanced effect (Fig. 7). Our
approach is based on a combination of two different assays that
makes it possible to study α-synuclein aggregation at low pH
values. In future studies, following approaches such as those
recently described for Aβ37, it will be important to validate the
results obtained through this approach with direct measurements
of oligomer populations.
These results illustrate how relatively minor chemical mod-
ifications can have a significant impact on the microscopic steps
in the aggregation process and reveal how the inhibition of
































































































































Fig. 5 Effects of the flavone derivatives on the reactive flux towards α-synuclein oligomers. a–g Normalised changes in ThT fluorescence when 20 µM
monomeric α-synuclein with 50 nM preformed seed fibrils at pH 4.8 and 37 °C was incubated in the absence (DMSO control (black)) and presence of
10 µM of flavone derivatives, denoted by the dark coloured curve (flavone (a), 5,6,7-trimethoxyflavone (b), apigenin (c), morin (d), baicalein (e),
scutellarein (f), 7-hydroxyflavone (g)). The normalised reactive flux towards oligomers, ϕ (see Eq. 8), which has a characteristic bell shape, is plotted
against time and overlaid for each flavone derivative at 0.5 molar equivalents of compound, relative to α-synuclein, denoted by the light grey curve (DMSO
control) and the lightly coloured curves.
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oligomer formation should balance oligomer generation by sec-
ondary nucleation and oligomer depletion by fibril elongation.
Thus the interplay between effects on the respective rates r2 and
r+ should be carefully considered when a potential lead com-
pound is developed. Overall, our study provides a route for the
screening of compounds that reduce the number of α-synuclein
oligomers, which can be used as a starting point in drug discovery
pipelines.
Methods
Reagents. ThT UltraPure Grade (ThT >95%) was purchased from Eurogentec Ltd
(Belgium). Sodium phosphate monobasic (NaH2PO4, BioPerformance Certified
>99.0%) and sodium phosphate dibasic (Na2HPO4, ReagentPlus, >99.0%) were
purchased from Merck (formerly Sigma Aldrich), UK.
Protein preparation. Recombinant α-synuclein was expressed and purified as
described previously35,36,39. Escherichia coli BL21 Gold (DE3) cells were trans-
formed with a human α-synuclein-encoding pT7-7 plasmid and grown in LB
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(2xγT) media in the presence of ampicillin (100 μg/mL). Cells were induced with
1 mM IPTG, cultured at 37 °C overnight and harvested by centrifugation in a
Beckman Avanti J-20 centrifuge with a JA-8.1000 rotor for 20 min at 4000 rpm
(Beckman Coulter, Fullerton, CA) and 4 °C. The cell pellet was resuspended in
10 mM Tris–HCl (pH 7.7) and 1 mM EDTA and lysed by sonication. The cell
suspension was centrifuged for 20 min at 18,000 rpm at 4 °C, and the supernatant
was subsequently boiled by suspension in a water bath at 80–95 °C for 20–25 min.
The boiled supernatant was once again centrifuged for 20 min at 18,000 rpm at 4 °C
to pellet heat-denatured proteins. In all, 10 mg/mL streptomycin sulfate was added
to the supernatant to precipitate DNA and rolled for 15 min at 4 °C on a benchtop
rolling system. To pellet precipitated DNA, the mixture was centrifuged at for
20 min at 18,000 rpm at 4 °C and the supernatant was collected. To precipitate
α-synuclein, ammonium sulfate was added to the supernatant to yield a final
concentration of 361 mg/mL and the mixture was rolled for 30 min at 4 °C on a
benchtop rolling system before being centrifuged for 20 min at 18,000 rpm at 4 °C.
The α-synuclein-containing pellet was resuspended in 25 mM Tris–HCl (pH 7.7)
and dialysed using a 3500 MWCO membrane in 4 L 25 mM Tris–HCl (pH 7.7). α-
Synuclein was purified by ion exchange on a Q-SepharoseTM HP HiScaleTM 26/20
column (Cytiva, formerly GE Life Healthcare, USA) before size exclusion on a
HiLoadTM 16/600 SuperdexTM 75 pg column (Cytiva, formerly GE Life Healthcare,
USA) into the appropriate experimental buffer. To determine the concentrations in
solution, we used the absorbance value of the protein measured at 275 nm and an
extinction coefficient of 5600M−1 The protein solutions were divided into aliquots,
flash frozen in liquid N2 and stored at −80 °C until required for use.
Seed fibril formation. Seed fibrils were produced as described previously35,36,39.
Five hundred microlitres of α-synuclein at 100–200 μM concentrations were
incubated in 20 mM phosphate buffer (pH 6.5) for 48–72 h at ≈40 °C and stirred at
1,500 rpm with a Teflon bar on an RCT Basic Heat Plate (IKA, Staufen, Germany).
Fibrils were divided into aliquots, flash frozen in liquid N2 and stored at −80 °C
until required for use. For experiments at pH 6.5 (utilising μM fibril concentra-
tions), the fibril stock was sonicated for between 0.5 and 1 min using a probe
sonicator (Bandelin, Sonopuls HD 2070, Berlin, Germany), using 10% maximum
power and a 50% cycle. For experiments at low pH utilising nM fibril con-
centrations, the fibril stock was diluted to 10 μM in water and sonicated 3 times for
5 s at 10% maximum power and 50% cycles using the probe sonicator.
Measurement of aggregation kinetics. Wild-type α-synuclein was incubated at
the concentrations indicated and in the presence of 50 μM ThT and preformed α-
synuclein fibrils at 37 °C33,35,39. The change in the ThT fluorescence signal was
monitored using a Fluostar Optima or Polarstar Omega fluorescence plate reader
(BMG Labtech, Aylesbury, UK) in bottom reading mode under quiescent condi-
tions. Corning 96-well plates with half-area (3881, polystyrene, black with clear
bottom) non-binding surfaces sealed with aluminium sealing tape were used for
each experiment.
Transmission electron microscopy. Wild-type α-synuclein was incubated for
100 h in Corning 96-well plates with half-area (3881, polystyrene, black with clear
bottom) non-binding surfaces at the concentrations indicated at 37 °C under
quiescent conditions and in the presence of 0.25% preformed fibrils of α-synuclein,
as per the secondary nucleation protocol. The endpoint reaction mixture was
removed from the plate and adsorbed onto 400 mesh carbon-coated copper grids,
stained with 2% aqueous uranyl acetate and visualised with a FEI Tecnai G20
transmission electron microscope, operating at 200 kV, 20 µm objective aperture,
and images were recorded with an AMT camera.
Determination of the fibril elongation rate. In conditions where seed con-
centrations are high (≃µM), and where primary nucleation can be neglected, the






where M(t) is the fibril mass concentration at time t, P(0) is the initial number
concentration of fibrils, m(0) is the initial monomer concentration and k+ is the
rate of fibril elongation. By fitting a straight line to the early time points of the
aggregation reaction M(t), a value for 2k+P(0)m(0) can be found35,36,39, allowing
the initial aggregation rate constants in the presence of the compounds to be
calculated and compared.
Determination of the secondary nucleation rate. For secondary nucleation
experiments at low pH with low (≃nM) seed concentrations, the fibril mass frac-
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where mtot denotes the total concentration of α-synuclein monomers. The terms a,
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The terms λ and κ represent combinations of the effective rate constants for








Fig. 6 Characterisation of the interplay between the effective rate constants for elongation and secondary nucleation in oligomer formation. a General
schematic of the time dependence of the oligomer flux in the α-synuclein secondary nucleation assay. b Normalised area under the curve of the reactive
flux towards α-synuclein oligomer formation relative to the DMSO control. c Normalised peak height of the reactive flux towards α-synuclein oligomer
formation relative to the DMSO control. d Relative peak time of the reactive flux towards α-synuclein oligomer formation relative to the DMSO control.
e The effect of apigenin on the features of the oligomer flux (ϕ), where AUC, PH and PT denote “area under curve”, “peak height” and “peak time”,
respectively. f Illustration of the manner in which the interplay between secondary nucleation and elongation events determines the oligomer population
during aggregation. g Visualisation of the interplay of r2 and r+ in affecting oligomer flux peak parameters (Eqs. 13–19), with black points indicating the
different flavone derivatives. Compounds considered the most effective in each instance are indicated by coloured rings, in particular apigenin (blue), 5,6,7-
trimethoxyflavone (pink), 7-hydroxyflafone (purple) and scutellarein (tan). In b–d, error bars represent the standard error of the mean of three biological
replicates each containing three technical replicates. Statistical analyses represent two-way ANOVA results where *P≤ 0.0332, **P≤ 0.0021, and ****P≤
0.0001.
(3,0,1)






















































Fig. 7 Structure–kinetic activity effect of flavone compounds based on
distribution of hydroxyl groups. Compounds are plotted according to their
ability to reduce oligomer flux peak height (x-axis) and area (y-axis).
Apigenin (bottom left region of the plot) confers the greatest potency.
These findings suggest that the positioning of hydroxyl groups is important
for determining the potency of flavone derivatives. More specifically, we
define a ‘fingerprint’ for this positioning in terms of the number of hydroxyl
groups on the left-hand side, central region and right-hand side (regions
denoted in figure inset), respectively, finding that the (2,0,1) fingerprint of
apigenin is the most effective one.
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where kn and k2 are the rate constants for primary and secondary nucleation, and
nc and n2 denote the reaction orders of primary and secondary nucleation,
respectively. In this case, the parameter c was employed as a global fitting
parameter for all data sets yielding 0.3, corresponding to a reaction order for
secondary nucleation of about n2≃ 4.
The fibril number concentration, P(t), is subject to amplification and is
described by dP tð Þdt , determined in this case at the reaction half-time
39. Change in α-
synuclein fibril concentration under these conditions can be approximated to the
change in P, described by the change in dM tð Þdt . Thus the model describing the
autocatalytic fibril amplification of α-synuclein stems from the linear equation for
monomer consumption as described in the case for determining the rate of α-
synuclein elongation, k+, but describes the change in fibril number concentration
over time in terms of the total α-synuclein monomer concentration in the reaction,
mtot, and the first derivative of M(t), described by primary and secondary













where and m(t) is the α-synuclein monomer concentration at the start and at time t
and dPðtÞdt was determined at the half-time for each reaction and compared, per
compound, to the dimethyl sulfoxide control sample to give an effective rate of
fibril amplification, r235,36,39.
Analysis of on-pathway oligomer formation over time. The theoretical pre-
diction of the time evolution of the reactive flux towards oligomers (Figs. 6a–g and















where r+= 2k+m(0) is the apparent elongation rate constant extracted from the
high-seed α-synuclein aggregation experiments for each respective com-
pound (here we use m(0) = mtot).
This expression for ϕ(t) can be derived as follows39. The flux towards oligomers







































Substituting Eq. 2 into Eq. 8 yields a description of ϕ in terms of the generalised
logistic fit parameters as
ϕðtÞ ¼ mð0Þaκ
2eκt
2rþ 1þ ac eκt
 2 ð12Þ
from which the area under the curve of ϕ, corresponding to the total amount of
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Equation 12 may also be used to calculate the peak height and peak time of ϕ,













which yields a description for the peak height of ϕ as
















as scaling relationships for peak time and peak height, respectively. Thus the
parameters of area under the curve, peak height and peak time may all be
approximated in terms of the fitting parameter κ, which, in turn, represents a
combination of the effective elongation rate, r+, and the effective secondary
nucleation rate, r2.
Data availability
The data that support this study are available from the corresponding author upon
reasonable request.
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